Previous Close | 11.97 |
1-Year Change | 12.39% |
6-Months Change | 15.88% |
3-Months Change | 15.32% |
Moving Avg (50d) | 11.153 |
Moving Avg (200d) | 11.231 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.55B |
Beta (3-Years) | 1.09 |
Revenue Growth (ttm) | 29.98% |
Net Profit Margin (ttm) | -26.23% |
Return On Assets (ttm) | -15.95% |
EPS (ttm) | -0.39 |
PE Ratio (ttm) | -30.69 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners... Wikipedia